Abstract: Growth differentiation factor 11 (GDF11) and myostatin (or GDF8) are closely related members of the transforming growth factor β superfamily and are often perceived to serve similar or overlapping roles. Yet, despite commonalities in protein sequence, receptor utilization and signaling, accumulating evidence suggests that these 2 ligands can have distinct functions in many situations. GDF11 is essential for mammalian development and has been suggested to regulate aging of multiple tissues, whereas myostatin is a well-described negative regulator of postnatal skeletal and cardiac muscle mass and modulates metabolic processes. In this review, we discuss the biochemical regulation of GDF11 and myostatin and their functions in the heart, skeletal muscle, and brain. We also highlight recent clinical findings with respect to a potential role for GDF11 and/or myostatin in humans with heart disease. Finally, we address key outstanding questions related to GDF11 and myostatin dynamics and signaling during development, growth, and aging. (Circ Res.
G rowth differentiation factor 11 (GDF11), also known as bone morphogenetic protein 11 (BMP11), and its homolog myostatin (also known as GDF8) are closely related members of the transforming growth factor β (TGFβ) superfamily. 1, 2 Myostatin plays an evolutionarily conserved role in antagonizing postnatal muscle growth, limiting both the number and size of individual muscle fibers. 1 Hence, disruption of the myostatin gene or targeted inhibition of myostatin protein triggers hypermuscular phenotypes in many mammals and fish. [3] [4] [5] Myostatin function also has been implicated in postnatal glucose metabolism and adipogenesis. 6 GDF11, in contrast, plays a broad role during mammalian development, regulating anterior/posterior patterning, formation of the kidney, stomach, spleen and endocrine pancreas, and olfactory neurogenesis.
2,7-11 GDF11's functions in postnatal tissues are less explored, partly because of the perinatal lethality of Gdf11-knockout mice, 2, 7 which exhibit homeotic skeletal transformations, cleft palate, and renal agenesis (Table) .
Further highlighting the differences in myostatin and GDF11, myostatin mRNA is predominantly detected in skeletal and cardiac muscle, whereas GDF11 mRNA is detected broadly in numerous tissues 12 and is most abundant in the kidney and spleen. 24 Both GDF11 and myostatin are found in the bloodstream, and while the functional implications of their circulation are still under investigation, their systemic presence implies that these proteins may act as hormonal signals. Given their high sequence similarity, it was expected that many of the features and functions of these 2 ligands should overlap. However, a growing number of studies have described disparities in their actions, sparking debate regarding their respective involvement in particular physiological processes. Here, we discuss the molecular properties of GDF11 and myostatin, their roles in regulating different organ systems, and the challenges encountered in studying these proteins, which have contributed to recent controversies about their biological roles.
Biochemical Regulation of GDF11 and Myostatin
The TGFβ family comprises >30 structurally related, yet functionally distinct ligands. This family can be subdivided into 3 subclasses: the TGFβs, BMPs, and activin/myostatins. GDF11 and myostatin belong to the activin/myostatin subclass and share 90% sequence identity within their mature, signaling domain. Similar to other TGFβ proteins, both GDF11 and myostatin are synthesized as precursor molecules where an N-terminal prodomain is cleaved from a C-terminal signaling or mature domain by a furin protease ( Figure 1A ). The mature ligands are propeller-shaped, disulfide-linked dimers that initiate signal transduction by engaging 2 type II receptors and two type I receptors using convex and concave surfaces, respectively 29 ( Figure 2 ). The molecular structure of myostatin has been extensively investigated, including 2 x-ray crystal structures of myostatin in complex with 2 known antagonists. 30, 31 In contrast, GDF11 is less well characterized, and much of what is known for myostatin has been inferred for GDF11. However, the unbound x-ray crystal structure of GDF11 was recently determined revealing the classic propellershaped structure with subtle differences between myostatin and GDF11, particularly in receptor-binding epitopes. 32 Therefore, although many structural and regulatory mechanisms are shared between these 2 ligands, growing evidence also points to unique features of GDF11 and myostatin biology.
Role of the Prodomain in Latency and Activation
Although mature GDF11 and myostatin ligands share substantial sequence identity, their prodomains are only 52% identical (Figure 3 ). Like other TGFβ members, the GDF11 and myostatin prodomains aid in folding of the mature dimeric ligand. 34, 35 However, unlike most TGFβ ligands, GDF11 and myostatin remain tightly bound to their prodomains after cleavage by furin-like proteases, [36] [37] [38] [39] [40] [41] and are thereby held in a latent state, unable to bind receptors. Ligand activation requires additional cleavage of the prodomain by a tolloid-like (TLD) metalloproteinase. 38, 39 Compared with other ligands, myostatin is inefficiently processed by furin, leaving a significant amount of unprocessed and presumably inactive protein. 36, 37 However, a single-nucleotide polymorphism for the mutation K153R 42 dramatically improves furin processing, but has no effects on TLD activation 43 ( Figure 3B ). Interestingly, this allelic variant was found at higher frequency in 2 centenarian cohorts, when compared with controls, 44 although the implications of this polymorphism in terms of longevity and maintenance of muscle mass and strength have yet to be definitively established. [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Although GDF11 has similar furin and TLD recognition sequences, it is not known if sequence variations, especially in the surrounding areas, which are more divergent, alter furin and/or TLD processing of GDF11 ( Figure 3B ).
Structural details of the latent state have yet to be described for GDF11 and myostatin. Still, despite differences in mechanism of activation (discussed below), the structure of TGFβ1 in complex with its prodomain 33 offers general insight into the molecular interactions driving latency. The latent structure of TGFβ1 has a ring-like appearance orchestrated by a centrally positioned mature dimer blanketed by the prodomains from each monomer 33 ( Figure 3A ). Ligand inhibition is mediated through interactions of the helical N terminus (α1) with the type I receptor site and a latency lasso where the prodomain wraps around the ligand fingertips toward the type II receptor site. 33 Consistent with this structure, myostatin prodomain residues 43-115 are necessary and sufficient to inhibit ligand activity. 54, 55 Interestingly, this region contains the TLD proteolytic site 12, 29 and is highly conserved with GDF11, suggesting that it serves a similar role in regulating GDF11 ( Figure 3B) .
Nonetheless, the mechanism for TGFβ activation differs from that of GDF11 and myostatin. 56, 57 The TGFβ latent complex exists in the extracellular matrix covalently bound to the latent transforming growth factor β protein 1 (LTBP1) via N-terminal disulfide linkages, a feature not known to occur for GDF11 and myostatin. [58] [59] [60] In addition, the apex of the TGFβ latent complex interacts with α V β VI integrin. 56, 57 The combination of these 2 interactions tether the latent TGFβ complex at both ends, such that cellular contractile forces release the mature TGFβ ligand from the prodomain. 33, 56, 57 Although there is no evidence that myostatin or GDF11 latent complexes are covalently bound to an LTBP, these latent complexes do interact with the extracellular matrix components LTBP3 and perlecan. 37, 61 The purpose of these interactions remains unknown, but possibly relates to ligand activation, as binding to LTBP3 can prevent furin processing and overexpression of LTBP3 in skeletal muscle increase muscle mass. 37 Thus, interactions with extracellular matrix components may fine-tune the activity of myostatin and GDF11, and dissimilarities in GDF11 and myostatin prodomain sequences ( Figure 3 ) could allow for unique extracellular matrix interactions across tissues.
Receptor Utilization by GDF11 and Myostatin
Similar to the activin-type ligands, both GDF11 and myostatin predominantly use the type II receptors activin receptor kinase II-A and type II receptors activin receptor kinase II-B and the type I receptors activin receptor-like kinase 4 (ALK4) and ALK5 to elicit signal transduction via SMADs 2 and 3 40, 62, 63 ( Figure 2B ). GDF11 also can signal through an additional type I receptor, ALK7, although its biological role remains undetermined. 62 Unlike the BMPs, the TGFβ and activin/myostatin subclasses exhibit high affinity for the type II receptor and 21 Cardiac hypertrophy and heart failure, but cardiac function is restored after several weeks 22, 23 low affinity for the type I receptor. 29 The type II receptors for the BMP and activin subclasses bind on the concave surface of the fingers, whereas TGFβs bind the type II receptor more distally, toward the fingertips. 29 This positioning facilitates a cooperative binding interaction between the type II and type I receptors, as shown by the structure of the TGFβ3:TBRII:ALK5 receptor complex. 64 In contrast, the receptors bind BMPs on opposite sides of the fingers, and thus are unable to interact with one another, as described in the BMP2: type II receptors activin receptor kinase II-B:ALK3 complex. 65 The ternary receptor configuration for activin/ myostatin has yet to be determined, as detailed binding and structural studies have been hampered by the low affinity for their type I receptors. 29 Using structural data as a guide to denote the approximate receptor interfaces, 64, [66] [67] [68] it is likely that GDF11 and myostatin bind type II receptors similarly because residues in this location are identical (Figure 4) . However, residues in the type I site, specifically the prehelix loop and wrist helix (Figure 4) , are divergent between GDF11 and myostatin, suggesting that type I receptor binding might differ, especially in the utilization of ALK7. Supporting this notion, introduction of the myostatin prehelix loop into Activin A confers signaling through ALK5. 30 Similar chimeric protein studies should help to reveal the biological consequences of sequence differences between GDF11 and myostatin at the receptor interface. Furthermore, with growing evidence indicating the importance of coreceptors in assembling TGFβ ligand complexes, [69] [70] [71] [72] [73] [74] [75] [76] further studies are needed to define their roles in GDF11 and myostatin signaling. 
Regulation of GDF11 and Myostatin by Extracellular Binding Proteins
Signaling by GDF11 and myostatin is regulated by extracellular-binding proteins that are typically thought to function as antagonists. These include follistatin, follistatin-like 3 (FSTL3), decorin, and growth/differentiation factor-associated serum proteins 1 and 2 (GASP1 and GASP2). 40, [77] [78] [79] [80] [81] Structural studies indicate that 2 follistatin or FSTL3 molecules symmetrically embrace the ligand to block both receptor epitopes. 30 ,31 FSTL3 and follistatin similarly contain an N-terminal domain followed by tandem follistatin domains. The N-terminal domain binds in the concave type I receptor slot where GDF11 and myostatin show the highest divergence. [30] [31] [32] However, mutagenesis studies and comparison with other follistatin-ligand structures indicate that the follistatin N-terminal domain is highly plastic and can accommodate diverse type I interfaces. 30, 31, [82] [83] [84] Therefore, sequence differences likely have minimal impact on GDF11 and myostatin antagonism by follistatin. Sequence differences are also unlikely to impact the increased binding to cell surface-localized heparin/heparin sulfate, and the subsequent acceleration of ligand degradation that occurs when follistatin is bound to myostatin. 30 This A B Figure 3 . Structural organization of the transforming growth factor β1 (TGFβ1) prodomain and comparison of growth differentiation factor 11 (GDF11) and myostatin (MSTN) prodomains. A, Structure of the TGFβ1-prodomain latent complex (PDB 3RJR 33 ). Key regions identified in the TGFβ prodomain for conferring inhibition of the mature domain are highlighted (dotted box on the left is shown as the inset). B, Sequence alignment of human GDF11 and myostatin prodomains with topology based on the TGFβ structure. Known proteolytic sites and residues important for each proteolytic event are highlighted (furin: red and TLD: orange).
by guest on http://circres.ahajournals.org/ Downloaded from interaction is known to regulate myostatin signaling within skeletal muscle 85, 86 and a similar mode of regulation may exist for GDF11. Interestingly, FSTL3 does not bind heparin and, therefore, readily escapes the cell surface to enter circulation. 87 Thus, the distinct localizations of follistatin-type antagonists provide an intriguing mechanism for differentially modulating the actions of circulating versus locally produced GDF11 and myostatin.
In contrast to broad TGFβ ligand antagonism by follistatin-type molecules, GASP1 and GASP2 selectively inhibit GDF11 and myostatin. 77, [88] [89] [90] [91] GASP proteins contain 6 domains, a whey acidic protein domain, follistatin domain, immunoglobulin-like domain, 2 tandem kunitz domains, and a netrin-like domain. 77, 92 The follistatin domain is the primary driver of ligand antagonism. 91 Despite a similar domain layout, GASP1 binds myostatin in a unique 1:1 ratio, forming an asymmetrical complex, whereas GASP2 binds symmetrically in a 2:1 ratio, 79 similar to follistatin or FSTL3. 30, 31, 88 Interestingly, C-terminal truncation of GASP1 induces 2:1 binding and weaker affinity for myostatin, similar to that of GASP2. 88, 90, 91 GASP proteins antagonize signaling by preventing ligand binding to the type II receptor, 90, 93 an intriguing mechanism given that GASP maintains unique specificity for GDF11 and myostatin, despite conservation of the type II receptor epitope among the activin/myostatin subclass. This observation suggests that steric forces and/or additional molecular contacts (eg, in the type I epitope) are likely important in defining this unique ligand-antagonist relationship.
In summary, GDF11 and myostatin are regulated by specific and nonspecific interactions at nearly every step from biosynthesis to engagement with their cognate receptors. Given that sequence divergence exists between the GDF11 and myostatin prodomains, and to a lesser extent in the mature domains, it remains important to determine if the distinct biological functions of these proteins are driven, in part, by these molecular differences.
Signaling by GDF11 and Myostatin
Canonical TGFβ signaling is mediated through a series of SMAD proteins. Receptor binding by either GDF11 or myostatin induces phosphorylation and activation of the receptorregulated SMAD (R-SMAD) proteins SMAD2 and SMAD3. Subsequently, the phosphorylated R-SMAD proteins assemble to form oligomeric complexes with the common SMAD (coS-MAD) SMAD4, and this complex accumulates in the nucleus to regulate gene expression through direct and indirect DNA binding ( Figure 2B ). Cellular responses to SMAD2/3 activation are highly context dependent, and the presence or the absence of particular transcriptional cofactors, DNA-binding partners and chromatin modifiers can dramatically alter the ultimate output of ligand binding. 94, 95 GDF11 and myostatin may also signal through noncanonical (ie, non-SMAD) pathways, including ERK, JNK, and p38 MAPK ( Figure 2B ), 22, [96] [97] [98] adding further complexity.
The transcriptional targets of GDF11 and myostatin signaling remain incompletely defined. A recent study compared gene-expression changes after stimulation of human primary muscle cells with GDF11 or myostatin. 98 Only a few differentially represented transcripts were identified, suggesting that GDF11 and myostatin gene regulation may be essentially identical. 98 However, this analysis was limited to a single cell type and neither ligand activated a robust gene-expression signature (the highest observed Fold Change values were only ≈4-fold for either ligand). Thus, further experiments are needed to clarify potential differences in the transcriptional output of GDF11 and myostatin signaling in different cell types and physiological contexts.
GDF11-Related Pathways in the Heart
The incidence of myocardial infarction and heart failure increases with age, 99 and aging increases mortality risk with any given infarction event. 100 TGFβ signaling regulates responses to myocardial ischemic injury, 101, 102 with recent studies suggesting possible roles for GDF11, myostatin, and FSTL3 in the heart.
Myostatin in the Heart
Myostatin is best known for inhibiting skeletal muscle growth, 1, 3 but genetically engineered models have demonstrated an additional function in cardiac tissue. Myostatin is expressed in fetal and adult hearts, 103 and its expression increases in patients with decompensated heart failure 104 and congenital heart disease. 105 Myostatin protein levels rapidly increase after ischemia, 106 and its circulating levels increase in mice after transverse aortic constriction-induced hypertrophy. 21 Germ-line inactivation of myostatin does not cause cardiac hypertrophy and does not attenuate cardiac fibrosis in dystrophin-deficient mice, indicating that myostatin does not function in cardiac muscle in a manner similar to skeletal muscle. 107 However, other experiments reveal that myostatin-null mice develop increased heart and body weights. Myostatin −/− mice (28-to 30-month old) were reported to have increased normalized heart mass at death compared with myostatin +/+ and myostatin +/− mice. 108 Aged mice with myostatin deletion have improved fractional shortening, smaller left ventricle diastolic diameters, and less fibrosis compared with aged wild-type mice. 109 Heineke et al 21 compared deletion versus overexpression of myostatin in cardiomyocytes. Myostatin deletion in cardiomyocytes did not prevent left ventricular decompensation under pressure overload, whereas transgenic overexpression of myostatin in the heart inhibited cardiac growth. 21 Inducible genetic deletion of myostatin in adult mouse cardiomyocytes leads to dramatic deterioration of cardiac function and high mortality, as well as increased glycolysis and glycogen storage, revealing the importance of endogenous myostatin for adult cardiomyocyte metabolism. 23 Thus, myostatin likely participates in cardiac growth and metabolism, although the experimental findings have not been as consistent in the heart as in skeletal muscle.
Cardiac Effects of GDF11
GDF11 is expressed in cardiac tissue 18 but at lower levels compared with spleen, kidney, and skeletal muscle in mice. 24 We reported an antihypertrophic effect of GDF11 in aging mice. 24 Using heterochronic parabiosis, we reported reduced cardiac hypertrophy in aging mice that shared a common circulation with young mice. We further devised a sham parabiosis procedure wherein mice were joined but did not share a chimeric circulation. With heterochronic sham parabiosis, hypertrophy in old mice was not reduced, implying the presence of a circulating factor that regulated cardiac size. Proteomic studies identified GDF11 as a candidate for this antihypertrophic effect, and supplementing blood levels in old mice by daily intraperitoneal injection of recombinant GDF11 (rGDF11) protein reduced cardiomyocyte size and heart mass during 4 weeks. 24 In contrast, Smith et al 110 reported recently that injections of the same quantity of rGDF11 used by us in old mice (0.1 mg/kg, injected daily) did not alter cardiac structure or function. These apparently contradictory results may be explained, in part, by the different sources of rGDF11 and by a potential dose-dependent effect of GDF11. After the study by Smith et al, 110 we performed a dose-response analysis and demonstrated that for a given protein preparation, the reduction in cardiac mass by GDF11 is dose dependent; for recent protein preparations with improved quality control of protein concentration, a dose of 0.5 mg/kg reduced cardiac mass in 9 days. 111 Injection of rGDF11 rapidly activates SMAD signaling in cardiac tissue of both young and old mice, 111 which together indicate that exogenous GDF11 can regulate cardiomyocyte size and hypertrophy and highlight that doses and protein preparations used could affect the results of in vivo studies. 112 Given observations reported previously for genetic manipulation of myostatin expression, 22, 107, 108 it is likely that administration of recombinant myostatin could achieve a similar antihypertrophic effect, but this has yet to be tested. Furthermore, it remains to be determined if a similar effect can be achieved with other ligands that likewise activate the SMAD2/3 pathway, such as members of the TGFβs or activin subclasses. Finally, although most studies to date have focused on SMAD activation as a readout of signaling activity, it will be interesting to determine if cross talk with noncanonical pathways may achieve ligand-specific effects.
FSTL3 in Cardiac Tissue
FSTL3 is expressed in cardiac tissue 113 and its expression increases in end-stage failing myocardium in humans. 114 Heart mass, left ventricular and systolic pressure, and systolic arterial pressure are increased in FSTL3-deficient mice compared with wild-type mice. 115 In addition, experimental cardiac injury induces myocardial expression of the prosurvival TGFβ ligand, activin A, and one of its antagonist regulators, FSTL3, where it is thought that the relative expression levels of these molecules dictate cell survival after insult. Interestingly, cardiomyocyte-specific deletion of FSTL3 reduces infarct size and apoptosis, suggesting a detrimental effect of endogenous FSTL3 on the heart, whereas overexpression of FSTL3 inhibits the prosurvival effect of activin A.
116 FSTL3 also regulates cardiac hypertrophy induced by pressure overload. 113 Although no differences were seen between hearts of cardiac-specific FSTL3 −/− and wild-type mice in standard physiological conditions, FSTL3
−/− mice 113 exhibited attenuated myocardial hypertrophy and reduced left ventricular dilatation, and systolic dysfunction and interstitial fibrosis were reduced 113, 117 after transverse aortic constriction-induced pressure overload (transverse aortic constriction). These data suggest that endogenous FSTL3 regulates the heart in many circumstances and that induced expression of FSTL3 may have deleterious effects. It remains to be determined how cardiac insult and upregulation of FSTL3 may affect the heart over time with respect to GDF11 and myostatin levels, especially in the case for older populations where evidence suggests that GDF11 and/or myostatin levels decline with age. 111 Nevertheless, because FSTL3 inhibits multiple TGFβ family ligands, 118 cardiac effects of FSTL3 cannot be attributed to a particular ligand interaction at this time.
GDF11-Related Pathways in Skeletal Muscle
Skeletal muscle is composed of multinucleated, nondividing fibers. Repair of muscle fibers after severe damage invokes the regenerative activities of a unipotent population of muscle stem cells, known as satellite cells, which reside immediately adjacent to myofibers in adult muscle. Aging impairs both the homeostatic maintenance of muscle mass and muscle regenerative potential, and recent studies have focused on the potential role of GDF11-related signaling pathways in these age-associated changes.
Myostatin in Muscle Homeostasis and Repair
Prevailing views on GDF11 function in skeletal muscle and satellite cells have been greatly influenced by analogy to myostatin because of the high homology of their mature, C-terminal ligand domains (Figure 4) . Myostatin is expressed almost exclusively in mature and developing muscle and negatively regulates muscle mass. Targeted disruption of myostatin in mice produces a near doubling of adult muscle mass, with an increase in both the size and number of muscle fibers 1 and a shift toward more glycolytic fiber types. 1, 16 Whether the hypertrophic and hyperplastic phenotype of myostatin-null muscle reflects, in part, a release of myostatin-mediated inhibition on muscle satellite cells remains unclear. Although some studies suggest that myostatin inhibits satellite-cell proliferation, 119, 120 others have reported that it has no impact. 121, 122 Likewise, some groups have found increased numbers of satellite cells in myostatin-null muscle, 123 whereas others report slightly lower numbers. 121 Myostatin overexpression and supplementation studies suggest that high levels of myostatin can drive rapid muscle atrophy, 124, 125 although more moderate increases in myostatin do not detectably alter muscle mass. 126 Conversely, treatment of mice with the inhibitory myostatin propeptide induces muscle hypertrophy.
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GDF11 Effects in Muscle
In contrast to the profound effects of myostatin deficiency, muscle phenotypes are not prominent in GDF11-null mice, which exhibit defects in a variety of mesodermal, endodermal, and ectodermal lineages and die within 24 hours after birth.
2 Nonetheless, double mutants lacking both myostatin and GDF11 exhibit increased penetrance of renal, palatal, and skeletal abnormalities, 7 suggesting that myostatin can compensate to some degree for loss of GDF11 in GDF11-null mice. Studies to similarly assess possible redundancy of GDF11 and myostatin function in regulating muscle mass have been challenging because of the fact that GDF11-null mice die before the age at which myostatin-null mice begin to exhibit muscle phenotypes. However, analysis of mice with muscle fiber-specific deletion of GDF11 showed no changes in muscle mass or fiber type, and muscle-specific GDF11 deletion did not exacerbate the phenotype of myostatin-null animals. 7 These results suggest that GDF11 and myostatin may have distinct functions in skeletal muscle, or that GDF11's effects on muscle are mediated by GDF11 protein that is produced by nonmuscle tissues.
GDF11 has been implicated as a negative regulator of muscle development by studies in chick embryos and in cultures of differentiating C2C12 cells and primary human and mouse muscle myoblasts. In these systems, GDF11, much like myostatin, can block myogenic differentiation. 98, [128] [129] [130] Yet, other data suggest that GDF11's role in myogenesis may be more complex. Gdf11 mRNA levels in mouse skeletal muscle seem to peak during the most rapid phase of postnatal muscle growth and are higher in males than in females, despite males having greater muscle mass. 130 Gdf11 expression is also increased in the muscles of myostatin-null mice, which nonetheless exhibit accelerated muscle growth and increased muscle mass. 130 These data raise the possibility that GDF11's actions in muscle may not fully overlap with those of myostatin such that GDF11 cannot compensate fully for the loss of myostatin in muscle. Whether this lack of functional redundancy reflects differences in the biochemical properties and signaling activities of GDF11 and myostatin, or differences in their absolute levels in muscle, remains to be determined. Interestingly, ectopic GDF11 can induce expression of follistatin, 128 which as discussed above inhibits both GDF11 and myostatin signaling. Thus, GDF11 can initiate a negative feedback loop that may antagonize its own activity, as well as that of other activin/ myostatin ligands. The existence of such a feedback mechanism suggests the likely importance of maintaining signaling by these ligands within a tight physiological range.
Experiments using heterochronic parabiosis recently implicated GDF11 as a candidate regulator of aging phenotypes in the heart, muscle, and brain. [24] [25] [26] Consistent with this notion, satellite cells isolated from the uninjured muscle of aged mice that received daily intraperitoneal injection of rGDF11 for 4 weeks showed improved myogenic activity in ex vivo clonal assays and a reduced burden of DNA damage. In addition, aged animals supplemented with rGDF11 showed accelerated recovery from muscle injury in a cryoinjury model. 26 rGDF11 treatment in aged mice also improved neuromuscular junctions and myofibrillar and mitochondrial morphology, and increased average exercise endurance and grip strength without any detectable changes in muscle mass or fiber caliber. 26 Notably, the dosage of rGDF11 in these studies was similar to that reported previously to lack effects on muscle size in an in vivo rMSTN dosing study. 126 Interestingly, young mice in this study showed no differences in regenerative capacity after treatment with the same amount of rGDF11, suggesting that GDF11's beneficial effects on muscle were age dependent.
In contrast to the studies summarized above, a subsequent article questioned the beneficial effects of rGDF11 on muscle aging, reporting instead that supplementation of rGDF11 in aged mice has no effect and in young mice impairs muscle repair. Yet, it is important to note that the study design used by this group 98 differed significantly from that in the earlier studies. 26 From a reagent standpoint, the authors used rGDF11 from a different protein source and used a different dosing regimen. Furthermore, they assessed muscle regeneration in a more severe, cardiotoxin-mediated damage model, which ablates the majority of resident satellite cells 131, 132 and shows distinct temporal and spatial features of regeneration in comparison with cryoinjury. 133, 134 Thus, the different outcomes obtained in the 2 studies may reflect differences in experimental design, and comparison of the methods used could provide an avenue for discovering key mechanisms that determine GDF11's in vivo effects. For instance, the inability of rGDF11 to accelerate repair in the satellite-cell depleting cardiotoxin injury model 98 suggests that sustaining a sufficient pool of regenerative satellite cells may be essential for a beneficial effect on regeneration in response to rGDF11. Likewise, the possible negative impact of higher doses of rGDF11 in young mice 98 could indicate that rGDF11 exhibits antagonistic pleiotropy in young versus old animals, or that the precise timing and dosage of rGDF11 administration is critical in determining its in vivo effects.
It is also important to remember that rGDF11's impact on muscle repair in vivo likely represents the integrated effects of this growth factor on many different target cells. GDF11 signaling has been implicated in many biological processes, including vasculogenesis, 25 a process clearly documented to influence the efficiency of muscle repair. 135 Indeed, if the primary actions of GDF11 in vivo are on vasculature, this may explain the coordinated responses to systemic administration of this protein seen in skeletal muscle, heart, and brain, as each of these organs shows critical dependence on proper vascularization, a process which declines with increasing age. 136 The potential effects of changing levels of myostatin on aging muscle have also been examined. As mentioned above, human genomics studies suggest an association of the K153R polymorphism, thought to increase myostatin activity by enhancing furin processing, 43 with longer lifespan. 44 Interestingly, homozygosity for the K153R allele is extremely rare, and most R allele-carrying centenarians are heterozygous for this variant, a genotype that does not seem to alter muscle phenotypes in aged individuals. 50, 51, 53 Studies in mice also suggest that alterations of myostatin signaling may affect lifespan. A recent study of male myostatin +/+ , myostatin +/− , and myostatin −/− mice (n=38-42 mice per group) revealed an increase in both median and maximum lifespan of heterozygous animals, which showed a 30% decrease in circulating myostatin levels, when compared with wild-type controls. 108 In contrast, the median and maximal lifespan of myostatin −/− mice did not differ from wild-type. Replication of this study, with inclusion of female animals, should be illuminating, particularly as data from human subjects suggests sex-specific differences in the regulation of circulating myostatin levels with age. 137 Analogous studies of lifespan in GDF11 mutant mice are complicated by the developmental phenotypes exhibited by both GDF11 −/− and GDF11 +/− mice. However, Zhou et al 138 recently reported that levels of circulating GDF11 are heritable in genetically diverse inbred mouse strains and can be used to predict median lifespan, with higher GDF11 levels at middle age associated with longer lifespan. In addition, an overall positive impact of higher GDF11 and/or myostatin levels on lifespan, as well as muscle function, has been corroborated in invertebrate models. For example, overexpression of myoglianin, the fly ortholog of both GDF11 and myostatin, delayed the onset of age-related neuromuscular dysfunction and extended lifespan, while its inhibition hastened neuromuscular decline and caused premature death. 139 Studies in shrimp likewise implicate the ancestral form of GDF11/myostatin in supporting muscle growth and survival. 140 In summary, although more research is clearly needed, evidence across species implicates GDF11 as a candidate regulator of muscle homeostatic and regenerative function during aging and suggests that raising levels of circulating GDF11 might be helpful for some age-related muscle pathologies. Emerging evidence also implicates both GDF11 and myostatin in regulating longevity and suggests that even subtle variations in ligand activity can alter phenotypic outcomes. Although the mechanisms underlying these effects remain unclear at present, these data raise the possibility that systemic GDF11 could provide a useful biometric for mammalian aging.
GDF11 in the Brain
TGFβ family ligands have diverse and pleiotropic roles in the development and maintenance of the nervous system, and their effects can vary between ligands, target cell types, and an animal's developmental stage or age. Neurological effects of GDF11 have been best characterized in the developing olfactory epithelium, spinal cord, and retina, where GDF11 influences the timing and progression of neurogenesis as well as the ratios of different neural subtypes. 10, 11, 141 In the developing olfactory epithelium, GDF11 plays a critical role in an autoregulatory loop, wherein newly born olfactory receptor neurons and their immediate neuronal precursor cells signal to neighboring cells to limit the production of more olfactory receptor neurons. 10 Olfactory receptor neurons and immediate neuronal precursors secrete GDF11, which drives cell cycle exit by inducing upregulation of the cyclin-dependent kinase inhibitor p27 Kip1 . Loss of GDF11 augments proliferation of immediate neuronal precursors and increases the number of differentiated neurons. Conversely, enhanced activation of GDF11 by genetic deletion of follistatin leads to sharp decreases in the numbers of both immediate neuronal precursors and olfactory receptor neurons. In the spinal cords of mice lacking GDF11, neural progenitor cells fail to exit the cell cycle, the rate of neurogenesis is slowed, the ratios of neural subtypes are altered, and the positional identities of motor neurons are disrupted. [141] [142] [143] Interestingly, in the retina, GDF11 also controls the timing of neurogenesis, but through a mechanism that does not involve proliferation. 11 Instead, GDF11 controls the length of time that progenitor cells are competent to produce retinal ganglion cells, and thereby regulates the ratio of RGCs to photoreceptors and amacrine cells.
Compared with its role in the developing nervous system, less is known about the role of endogenous GDF11 in the mature nervous system. Northern blot analysis of tissues from adult rats (3-4 weeks of age) showed high expression of Gdf11 in dental pulp and brain. 12 In the same study, RNA in situ hybridization identified specific areas of Gdf11 expression in the brain, including the dentate gyrus of the hippocampus, the
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hypothalamus, and the Purkinje cell layer of the cerebellum. 12 It was recently demonstrated that systemic administration of rGDF11 in aged mice alters brain physiology. 25 Heterochronic parabiosis experiments showed that young systemic factors could reverse age-related neurogenic decline by enhancing neural stem cell production and, thereby increase adult neurogenesis and olfactory discrimination capacities. Furthermore, youthful blood factors induced remodeling of the aged vasculature, restoring cerebrovascular blood flow to its youthful levels. Systemic injection of rGDF11 recapitulated several beneficial effects of heterochronic parabiosis, including vascular remodeling of the aged blood vessels in the subventricular zone and increased numbers of neural stem cells in this area. rGDF11 also induced the proliferation of brain capillary endothelial cells and activated the SMAD2/3 pathway in vitro. The in vivo effects of rGDF11 were not as prominent as those seen with heterochronic parabiosis, suggesting that additional factors may be present in the young circulation that exerts these central nervous system effects. 144 Future studies testing different concentrations of rGDF11, 111 different treatment lengths, and coinjection of factors such as insulin-like growth factor 1 or epidermal growth factor that affect neural stem cell proliferation and/or vascular behavior may clarify this issue.
The central nervous system effects of rGDF11 are because of exogenous/circulating protein and not due to brain-derived GDF11, whose role in the adult/aged brain is not yet understood. It will be important to determine if systemically administered rGDF11 crosses the blood-brain barrier and acts directly on neurons and neural stem cells, or if its effects on the central nervous system are a by-product of its cerebrovascular effects. It will likewise be exciting to determine if an autoregulatory loop exists between circulating and endogenous GDF11 that could amplify its effects. Interestingly, the effects of systemic rGDF11 are consistent with a recent report that constitutive activation of ALK5, a type I receptor for GDF11 and multiple TGFβs, leads to increased adult neurogenesis and higher expression of c-Fos in newborn neurons in the adult hippocampus, more complex dendritic arborization, increased neural activity, and improved performance in memory tests. 145 In addition, TGFβ1 is neuroprotective in mouse models of Alzheimer disease and excitotoxicity, 146, 147 and a recent study also reported that GDF10, which activates similar intracellular pathways as TGFβ1, β2, β3, and GDF11, improves brain vasculature, increases neurite outgrowth, and enhances performance in behavioral assays in a mouse model of stroke.
148
Clinical Implications of GDF11 and Myostatin
Olson et al 149 investigated whether GDF11 and myostatin might have similar cardioprotective properties in humans to those demonstrated in mice. In 928 archived plasma samples in subjects with stable coronary heart disease from the Heart and Soul prospective observational cohort, they measured circulating levels of ligand using modified aptamers as binding reagents. 149 This assay does not discriminate GDF11 from myostatin; thus, the measured analyte is referred here as GDF11+myostatin. The aims of the study were to characterize the association of plasma levels of GDF11+myostatin in humans with (1) age, (2) left ventricular hypertrophy (LVH), and (3) cardiovascular events and all-cause mortality during a median follow-up of 8.9 years. The key findings were replicated in 971 subjects with stable coronary heart disease from the HUNT3 Norwegian cohort, with a median follow-up of 4.5 years.
GDF11, Myostatin, and Age
Analysis in patients revealed an inverse relationship of plasma GDF11+myostatin to age in the HUNT3 cohort ( Figure 5A ), which was also observed in the Heart and Soul cohort. 149 Despite the narrower age range of these human subjects compared with the extremes of age reported in mice, 24 significantly lower levels of GDF11+myostatin were detected in older compared with younger individuals in both patient cohorts. 149 This cross-sectional analysis likely underestimates the decline in GDF11+myostatin with age because GDF11+myostatin is inversely associated with all-cause mortality; thus, surviving older individuals enrolled in these cohorts likely had higher GDF11+myostatin concentrations than those older individuals who had died and whose potentially lower levels could not be captured. Although GDF11+myostatin levels were higher in males compared with females enrolled in this study, an agerelated decline in GDF11+myostatin levels was detected in both sexes. 149 In support, a recent study used mass spectrometry to quantify circulating myostatin specifically in human subjects without chronic disease, and likewise reported higher myostatin concentrations in younger men compared with younger women, but found sex-specific differences in the effects of age on myostatin levels (higher myostatin concentrations in older versus younger women and lower myostatin concentrations in older versus younger men). 137 Circulating levels of the antagonist FSTL3 increased with age in both sexes. 137 Thus, although this latter study 137 analyzed a much smaller cohort (only 40 individuals of each age/sex), together these reports 137, 149 highlight a potential influence of age, sex, and health status on GDF11+myostatin levels and are consistent with an age-related loss of function of these ligands in humans, either through diminished protein concentrations 149 or through increased inhibition of ligand activity.
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GDF11, Myostatin, and Cardiovascular and AllCause Mortality
A relationship of plasma GDF11+myostatin levels to cardiovascular events (heart failure hospitalization, stroke, and myocardial infarction), all-cause deaths and their composite end point were also demonstrated in 971 subjects in the HUNT3 cohort ( Figure 5B ). 149 In both the HUNT3 and Heart and Soul cohorts, there was a strong, graded relationship between plasma GDF11+myostatin and cardiovascular and mortality outcomes. 149 Participants in the highest quartile of GDF11+myostatin had markedly lower risk of individual types of events and their composite end point than those in the lowest quartile, both unadjusted ( Figure 5B ) and after multivariable adjustment.
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GDF11, Myostatin, and LVH
Of the 928 participants in the Heart and Soul cohort, 368 had LVH by echocardiography. 149 There was a significant, inverse, graded relationship between GDF11+myostatin and LVH, with 31% of participants in the highest quartile of GDF11+myostatin having LVH compared with 46% in the lowest quartile. 149 In sum, in 2 large independent cohorts of patients with stable coronary heart disease, lower levels of GDF11+myostatin were associated with notably higher rates of incident cardiovascular events and all-cause deaths as well as higher prevalence of LVH. Finally, GDF11+myostatin levels are lower among older compared with younger individuals. Taken in the context of mechanistic studies in mice, these findings in humans support the hypothesis that GDF11 and/or myostatin protect against adverse cardiovascular events and all-cause deaths. 149 More broadly, these findings support the hypothesis that agerelated decline in GDF11+myostatin contributes to cardiovascular aging and mortality in humans 149 as it does in mice.
Future Directions for Clinical Research
A significant interaction was present in the multiracial Heart and Soul cohort between race and GDF11+myostatin for the composite cardiovascular and all-cause mortality outcome. 149 Whites compared with non-whites had both lower levels of GDF11+myostatin and a stronger link between plasma GDF11+myostatin and adverse outcomes. As noted previously, GDF11+myostatin levels also varied by sex. 149 Accordingly, future studies should investigate in greater detail any racial and sex differences in GDF11 and myostatin levels and their relationship to outcomes.
As discussed above, several endogenous inhibitors of GDF11 have been reported. These inhibitors may antagonize other ligands in the TGFβ family, including myostatin and activin. 78, 79, 90 Heidecker et al 150 investigated the association of GASP1, FSTL3, and follistatin with cardiovascular outcomes and all-cause mortality in the Heart and Soul and HUNT3 cohorts, using the same archived plasma samples as for the aforementioned GDF11+myostatin analyses. High levels of FSTL3 were associated with increased risk of adverse cardiovascular events and all-cause mortality, and the effect of low levels of GDF11+myostatin and high levels of FSTL3 were additive. Subjects in the least favorable quartile of GDF11+myostatin (lowest) and its inhibitor FSTL3 (highest) had nearly 7-fold increased risk of cardiovascular events and all-cause mortality. 150 Thus, any future studies of human diseases will need to consider the levels of GDF11+myostatin, levels of their inhibitors and their interactions.
Any therapeutic targeting of GDF11 or myostatin in humans must consider its potential adverse effects. GDF11 has been reported to exacerbate anemia in the setting of ineffective erythropoiesis. 151 Blocking GDF11 alleviates anemia in a mouse model of β-thalassemia and also in humans. 152 Analysis of observational cohort studies may provide much needed clarity whether levels of GDF11 and/or myostatin are associated with any additional adverse outcomes.
Current Controversies
The suggestion that GDF11 may serve as an evolutionarily conserved age-dependent hormone in multiple organ systems [24] [25] [26] 139 raises possibilities for manipulating this signaling pathway to restore or preserve function in aging tissues. Yet, this provocative notion also presents a new and unexpected role for GDF11 within the TGFβ superfamily, and contrasts with studies of many other TGFβ family proteins in aging, which have frequently concluded that these molecules suppress healthy tissue function during aging, most notably by promoting tissue fibrosis and inflammation. [153] [154] [155] [156] Thus, it is not surprising that there has been some skepticism and even controversy surrounding these results. It is likely that much of this controversy reflects the fact that GDF11 is a relatively understudied member of the TGFβ superfamily, particularly compared with its close relative myostatin, and thus the tools for studying GDF11 biology are still evolving. In addition, given the substantial sequence conservation of GDF11 with myostatin, many have assumed that the functions of these proteins should be identical. 7, 98 Here, we discuss some of these controversies and suggest strategies to resolve the apparent discrepancies to advance our mechanistic understanding of GDF11 functions in organ physiology and aging.
Presence in Circulation and Direction of Change With Age of Circulating GDF11 Protein
In 2013, we reported a significant decline in systemic levels of GDF11 in aged, when compared with young mice. 24 This conclusion was based on an aptamer-driven analysis of serum from young (2 months.) versus old (24 months.) mice performed using Somalogics SomaMERs, 157 in combination with
Western blotting using a monoclonal antibody from abcam, which, at the time, was reported to be specific for GDF11. Subsequent reports from our group 111 and others 98, 149, 158 revealed that the SomaMER and mAb used in these initial studies cross react with myostatin, and so, although these studies are consistent with a reduction in the circulating pool of GDF11 and myostatin in aged animals, these data cannot discriminate the relative impact of aging on systemic levels of GDF11 specifically. A report from Egerman et al 98 argued that circulating levels of GDF11 might actually increase with age, based on the results of Western blot, RNA expression, and GDF11-specific immunoassay. However, the Western results reported by this group were based on quantification of a ≈25-kDa immunoreactive band, the approximate size of the disulfide-linked mature ligand dimer, which was present in samples that had been reduced and denatured before Western blot analysis. Puzzled by this observation (because the blotting conditions should have reduced the dimeric ligand to monomer), we reproduced these experiments and confirmed that the ≈25-kDa band does increase with age. However, we further demonstrated that this band is composed of serum immunoglobulin, known to increase with age, 159 and not GDF11 or myostatin. 111 As expected, under denaturing and reducing conditions, detection of GDF11 and myostatin in serum is limited to the ligand monomer of ≈12.5 kDa, which declines with age in the studies by Egerman et al, 98 as in previous reports. 24, 26 In addition, the RNA expression analysis reported by Egerman et al 98 was limited to skeletal muscle, which expresses GDF11 at substantially lower levels (2-to 3-fold) than other tissues (eg, the spleen and kidney, 24 which may represent the predominant sources of circulating GDF11 protein). Finally, their immunoassay results in rats and humans were extremely underpowered (eg, only 9 individuals >60 years old were assessed in the human studies, with no evaluation of health status) and did not yield statistically significant differences for either species.
Studies from this group and one other 110 also suggested that circulating levels of GDF11 may be low compared with myostatin, leading a third group 160 to argue that changes in circulating GDF11 levels are mostly irrelevant. However, published mass spectrometry data clearly demonstrate the presence of GDF11 protein in both human and mouse sera, 161 and many critically important bioactive hormones are present at low levels (ie, pg/mL) in circulation, including glucagon, interleukin 6, and tumor necrosis factor α. 162 Thus, it is difficult to infer biological relevance from protein concentration alone. Future studies to develop highly specific reagents for measuring systemic GDF11 levels using either quantitative mass spectrometry or antibody-based immunoassays that can reliably distinguish GDF11 from myostatin in the blood of both humans and mice, something that has not yet been accomplished 98, 110 will be essential to clarify the overall abundance and age-related changes of circulating GDF11 and myostatin proteins. Adding to the complexity, current methods 137, 160, 163, 164 only measure the total amount of protein and cannot account for the status of the ligand in the serum (eg, free, latent, or in complex with an extracellular antagonist). Finally, it is still unclear if GDF11 and myostatin act predominantly as systemic hormones or if they may exert their most potent effects locally through autocrine/paracrine mechanisms, which complicates interpretation of the impact on peripheral tissues of changing levels of these proteins in the blood. Thus, it will be important to clarify which cell types produce GDF11 and what pathophysiological stimuli may alter GDF11 and/or myostatin expression.
Effect of GDF11 Supplementation on Skeletal Muscle Regeneration in Old and Young Mice
Studies investigating the effects of exogenous rGDF11 on muscle regeneration have reported apparently discrepant conclusions. Although we reported 26 that rGDF11 reverses agespecific muscle phenotypes and improves muscle strength, endurance and regenerative potential, with no discernable effects in young mice, Egerman et al 98 argued instead that rGDF11 supplementation has no effect in aged mice and may slow regeneration in young mice. As discussed above, these different conclusions likely arise from differences in protein source and experimental design. Of particular importance is the use by Egerman et al 98 of a more severe cardiotoxin injury model, 131, 134 when compared with the milder cryoinjury model applied in our studies 26 and those that originally demonstrated rejuvenation of muscle repair by heterochronic parabiosis. 165 Furthermore, in their studies of young mice, Egerman et al 98 used a markedly different dosing schedule, shortening the preinjury treatment window from 28 to 3 days and lengthening post injury treatment from 7 to 14 days. They also used an unconventional analysis strategy that selectively focused on tiny fibers that lacked apparent nuclei. The reported in vitro studies, also, were different in design, with one group analyzing cells purified from uninjured muscle, 26 and the other cells purified from cardiotoxin-damaged muscle, 98 with distinct culture conditions and time points of analysis. Thus, discrepancies in the reported effects of rGDF11 on muscle repair and muscle satellite cells may reflect differences in the recombinant protein itself, in protein dosage and treatment schedule, in the severity or method of muscle damage and the consequent size of the residual muscle stem cell pool, or in the particular culture conditions and analysis strategies used. Future studies to compare these experimental conditions side-by-side are necessary to identify the key experimental variables that underlie the different outcomes. In addition, the development and use of genetic gain-and loss-of-function models, as well as careful dose-titration assays in mice of different ages and different muscle injury paradigms will be helpful in establishing phenotypic thresholds for the possible context-specific effects of rGDF11 in skeletal muscle.
Effect of GDF11 Supplementation on Cardiac Hypertrophy
Our studies published in 2013 24 and 2015 111 reported an antihypertrophic effect of rGDF11 administration by comparing heart weight/tibia length ratio in treated and control aging mice, whereas the study by Smith et al 110 reported no effects on the heart. As discussed above, this disagreement may relate to dose-dependent effects of rGDF11 on cardiac mass, but it is also important to emphasize that Smith et al 110 did not observe changes in body weight in rGDF11 injected mice, whereas we reported a significant decrease in body weight in by guest on http://circres.ahajournals.org/ Downloaded from aging mice with exogenous rGDF11. 111 Observations from our laboratories indicate that exogenous rGDF11 decreases body weight in old mice in a dose-dependent manner (unpublished data and studies by Sinha et al, 24 and Poggioli et al 111 ). Although rGDF11 directly activates SMAD signaling in cardiomyocytes, 111 it is also possible that the reduction in cardiac size with exogenous rGDF11 in vivo is because of an indirect effect of rGDF11. A systemic signal, possibly initiated by a reduction in body size or a change in a specific tissue, is plausible. For example, there is a clear evidence for cross talk between adipose tissue and cardiac 166, 167 and skeletal 139, 168, 169 tissues. Thus, any interpretation of a direct effect of rGDF11 on the myocardium must be considered in the context of its systemic effects.
In conclusion, GDF11 has emerged as an intriguing candidate in the regulation of vertebrate aging and considerable progress has been made in the analysis of its role in the progression of age-associated disease. Future investigation of GDF11 and myostatin biology and biochemistry will clarify the similarities and differences in the functions of these proteins and advance our understanding of organismal aging and disease.
